ReviewMaterials today. Bio2025
Application of nanoparticles in the treatment of acute lung injury: Current situation and future directions.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Safe and effective control of Mycoplasma gallisepticum: pharmacokinetic and residue profiling of doxycycline combined with quercetin nanomicelles.Veterinary research communications · 2026Article
- Review
- Nanozymes as Emerging Therapeutics for Asthma: A Redox-Responsive and Immunomodulatory Strategy.Biomedicines · 2026Review
- Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.Materials today. Bio · 2026Article
- Nanomedicine Strategies Against Biofilm-Associated Infections: Advances, Challenges, and Translational Barriers.MicrobiologyOpen · 2026Review
- Novel Carbon Dots Nanomaterials for the Precision Diagnosis and Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome: Mechanisms and Applications.International journal of nanomedicine · 2026Review
- Gut microbiota in acute lung injury/acute respiratory distress syndrome: mechanistic insights and therapeutic opportunities via the gut-lung axis.Frontiers in cellular and infection microbiology · 2026Review
- Inhaled bovine lactoferrin modulates the p47phox-MPO-NETosis axis in acute lung injury: implications for bioengineered nanomedicine in respiratory infections.Frontiers in immunology · 2026Article
- Adrenergic receptors: a key determinant of outcomes in bacterial pneumonia and bacterial sepsis-associated acute lung injury/acute respiratory distress syndrome through participation in pulmonary innate immune response.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are critical conditions characterized by disruption of the alveolar-capillary barrier, uncontrolled inflammation, and progressive hypoxemia, with mortality rates exceeding 40 %. While conventional therapies such as mechanical ventilation and glucocorticoids can partially alleviate symptoms, they face limitations, including low drug delivery efficiency, systemic toxicity, and inability to precisely regulate pathological microenvironments. Nanoparticles (NPs), which leverage their unique size effects, surface modifiability, and multifunctional integration capabilities, demonstrate advantages in targeted delivery, reduced systemic side effects, and multifunctional therapeutic potential and are emerging as novel tools to overcome current therapeutic bottlenecks. This review systematically summarizes the classification, mechanisms of action, and applications of NPs in ALI/ARDS treatment, while critically evaluating translational challenges and future development trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.